Compounds > 2-amino-4-chloro-6-methylpyrimidine
Page last updated: 2024-12-06

2-amino-4-chloro-6-methylpyrimidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID21810
CHEMBL ID1723906
CHEBI ID58960
SCHEMBL ID150686
MeSH IDM0075102

Synonyms (68)

Synonym
HMS1757D09
4-chloro-6-methyl-2-pyrimidinamine
CHEBI:58960 ,
AC-15862
am (nitrification inhibitor)
nsc 7892
einecs 227-018-3
4-chloro-6-methylpyrimidin-2-ylamine
nsc 23661
brn 0114297
ai3-08093
4-chloro-6-methyl-pyrimidin-2-ylamine
BB 0238494
nsc-7892
5600-21-5
pyrimidine, 2-amino-4-chloro-6-methyl-
am (inhibitor)
am (pesticide)
prepn. am
2-pyrimidinamine, 4-chloro-6-methyl-
nsc7892
nsc23661
nsc-23661
4-chloro-6-methylpyrimidin-2-amine
2-amino-6-chloro-4-methylpyrimidine
4-chloro-6-methyl-2-pyrimidinylamine
AE-848/06047015
4-chloro-6-methyl-pyrimidin-2-amine
2-amino-4-chloro-6-methylpyrimidine ,
MLS000389365 ,
smr000255638
2-amino-4-chloro-6-methylpyrimidine, 97%
STK397556
A1088
AKOS000111542
L001028
A8069
NCGC00246049-01
HMS2536F11
2-amino-4-chloro-6-methyl pyrimidine
5-25-10-00178 (beilstein handbook reference)
unii-8zbb1fm476
8zbb1fm476 ,
FT-0611102
AM20100378
2-amino-4-methyl-6-chloropyrimidine
4-chloro-6-methylpyrimidine-2-amine
2-amino-4-chloro-6-methyl-pyrimidine
2-amino-4-chloro-6methylpyrimidine
4-chloro-6-methyl-2-pyrimidineamine
SCHEMBL150686
SY011380
mfcd00006091
bdbm47756
cid_21810
4-chloranyl-6-methyl-pyrimidin-2-amine
(4-chloro-6-methyl-pyrimidin-2-yl)amine
W-105536
CHEMBL1723906
DTXSID5022229
F0827-0306
CS-W001984
Q27126362
AS-11855
du7 ,
2-amino-4-methyl-6-chlorpyrimidin
EN300-17079
Z56871954
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
nitrification inhibitorAny inhibitor added to nitrogen fertilizers which can reduce the rate at which ammonium is converted to nitrate. Under appropriate conditions, this can help reduce nitrogen losses through denitrification and leaching.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
aminopyrimidineA member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RGS7, partialHomo sapiens (human)EC50 (µMol)30.00000.14002.13004.7800AID1871
regulator of G-protein signaling 4Homo sapiens (human)EC50 (µMol)30.00000.13503.350610.0690AID1872
cardiac alpha tropomyosinSus scrofa (pig)EC50 (µMol)71.37501.83002.37402.9180AID504698
troponin I, cardiac muscleHomo sapiens (human)EC50 (µMol)71.37501.83002.37402.9180AID504698
troponin T, cardiac muscle isoform 3Homo sapiens (human)EC50 (µMol)71.37501.83002.37402.9180AID504698
regulator of G-protein signaling 19Homo sapiens (human)EC50 (µMol)30.00000.11503.175614.1300AID1884
regulator of G-protein signaling 16Homo sapiens (human)EC50 (µMol)30.00000.05303.625816.0000AID1888
troponin C, slow skeletal and cardiac musclesHomo sapiens (human)EC50 (µMol)71.37501.83002.37402.9180AID504698
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (11.11)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's6 (66.67)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.45 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.12 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610